475 related articles for article (PubMed ID: 24670645)
1. Cystathionine γ-lyase deficiency mediates neurodegeneration in Huntington's disease.
Paul BD; Sbodio JI; Xu R; Vandiver MS; Cha JY; Snowman AM; Snyder SH
Nature; 2014 May; 509(7498):96-100. PubMed ID: 24670645
[TBL] [Abstract][Full Text] [Related]
2. Neurodegeneration in Huntington's disease involves loss of cystathionine γ-lyase.
Paul BD; Snyder SH
Cell Cycle; 2014; 13(16):2491-3. PubMed ID: 25486189
[No Abstract] [Full Text] [Related]
3. Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.
Carbo M; Brandi V; Pascarella G; Staid DS; Colotti G; Polticelli F; Ilari A; Morea V
Int J Mol Med; 2019 Dec; 44(6):2223-2233. PubMed ID: 31638189
[TBL] [Abstract][Full Text] [Related]
4. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease.
Wang N; Gray M; Lu XH; Cantle JP; Holley SM; Greiner E; Gu X; Shirasaki D; Cepeda C; Li Y; Dong H; Levine MS; Yang XW
Nat Med; 2014 May; 20(5):536-41. PubMed ID: 24784230
[TBL] [Abstract][Full Text] [Related]
5. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional control of amino acid homeostasis is disrupted in Huntington's disease.
Sbodio JI; Snyder SH; Paul BD
Proc Natl Acad Sci U S A; 2016 Aug; 113(31):8843-8. PubMed ID: 27436896
[TBL] [Abstract][Full Text] [Related]
7. Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.
Gladding CM; Fan J; Zhang LY; Wang L; Xu J; Li EH; Lombroso PJ; Raymond LA
J Neurochem; 2014 Jul; 130(1):145-59. PubMed ID: 24588402
[TBL] [Abstract][Full Text] [Related]
8. Golgi protein ACBD3 mediates neurotoxicity associated with Huntington's disease.
Sbodio JI; Paul BD; Machamer CE; Snyder SH
Cell Rep; 2013 Sep; 4(5):890-7. PubMed ID: 24012756
[TBL] [Abstract][Full Text] [Related]
9. Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis.
Lee CY; Cantle JP; Yang XW
FEBS J; 2013 Sep; 280(18):4382-94. PubMed ID: 23829302
[TBL] [Abstract][Full Text] [Related]
10. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
[TBL] [Abstract][Full Text] [Related]
11. Glutathione redox cycle dysregulation in Huntington's disease knock-in striatal cells.
Ribeiro M; Rosenstock TR; Cunha-Oliveira T; Ferreira IL; Oliveira CR; Rego AC
Free Radic Biol Med; 2012 Nov; 53(10):1857-67. PubMed ID: 22982598
[TBL] [Abstract][Full Text] [Related]
12. The ubiquitin conjugating enzyme Ube2W regulates solubility of the Huntington's disease protein, huntingtin.
Wang B; Zeng L; Merillat SA; Fischer S; Ochaba J; Thompson LM; Barmada SJ; Scaglione KM; Paulson HL
Neurobiol Dis; 2018 Jan; 109(Pt A):127-136. PubMed ID: 28986324
[TBL] [Abstract][Full Text] [Related]
13. Mutant huntingtin expression in microglia is neither required nor sufficient to cause the Huntington's disease-like phenotype in BACHD mice.
Petkau TL; Hill A; Connolly C; Lu G; Wagner P; Kosior N; Blanco J; Leavitt BR
Hum Mol Genet; 2019 May; 28(10):1661-1670. PubMed ID: 30624705
[TBL] [Abstract][Full Text] [Related]
14. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
15. Neonatal iron supplementation potentiates oxidative stress, energetic dysfunction and neurodegeneration in the R6/2 mouse model of Huntington's disease.
Berggren KL; Chen J; Fox J; Miller J; Dodds L; Dugas B; Vargas L; Lothian A; McAllum E; Volitakis I; Roberts B; Bush AI; Fox JH
Redox Biol; 2015; 4():363-74. PubMed ID: 25703232
[TBL] [Abstract][Full Text] [Related]
16. Autophagy Activation by Transcription Factor EB (TFEB) in Striatum of HDQ175/Q7 Mice.
Vodicka P; Chase K; Iuliano M; Tousley A; Valentine DT; Sapp E; Kegel-Gleason KB; Sena-Esteves M; Aronin N; DiFiglia M
J Huntingtons Dis; 2016 Oct; 5(3):249-260. PubMed ID: 27689619
[TBL] [Abstract][Full Text] [Related]
17. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
[TBL] [Abstract][Full Text] [Related]
19. Loss of the thyroid hormone-binding protein Crym renders striatal neurons more vulnerable to mutant huntingtin in Huntington's disease.
Francelle L; Galvan L; Gaillard MC; Guillermier M; Houitte D; Bonvento G; Petit F; Jan C; Dufour N; Hantraye P; Elalouf JM; De Chaldée M; Déglon N; Brouillet E
Hum Mol Genet; 2015 Mar; 24(6):1563-73. PubMed ID: 25398949
[TBL] [Abstract][Full Text] [Related]
20. Increased TRPC5 glutathionylation contributes to striatal neuron loss in Huntington's disease.
Hong C; Seo H; Kwak M; Jeon J; Jang J; Jeong EM; Myeong J; Hwang YJ; Ha K; Kang MJ; Lee KP; Yi EC; Kim IG; Jeon JH; Ryu H; So I
Brain; 2015 Oct; 138(Pt 10):3030-47. PubMed ID: 26133660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
